Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2019 Feb 20;18(4):856–867. doi: 10.1158/1535-7163.MCT-18-0548

Figure 2. Inhibition of S1P1 enhances VEGF activation of endothelial VEGFR2.

Figure 2.

Mice were orally dosed with compounds for 2 hours (Ex82: 30 mpk, Sunitinib: 20 mpk) or 24 hours (DC101: 20 mpk) followed by iv injection of murine VEGF to activate VEGFR. Lungs were collected 5 minutes after VEGF stimulation and western blot analysis of lung lysates was performed to detect and measure VEGFR activation. The S1P1 inhibitor Ex82 increases VEGFR activation 1.8 fold (p-value<0.0001), while the VEGFR inhibitor DC101 decreases VEGFR activation by 53% (p-value <0.0004). Sunitinib was used as a control and 95% target inhibition was achieved (p-value <0.0001).